Add：5th Floor, Building 9, Nanjing Life Science and Technology Innovation Town, No. 568 Longmian Avenue, Jiangning District, Nanjing, Jiangsu, China
Nanjing Gritpharma Co .,Ltd is an innovative biomedical enterprise that has high growth, specializing in new drug research and development, technology transfer, technical service and new product industrialization.
At present, GRITPHARMA is founded by the main business backbone of the R&D team and the CEO,CSO from the original C & O. Our company has built a first-rate R&D platform and hardware facilities.
Nanjing Gritpharma Co .,Ltd
Innovation and research
Our company is oriented to meet clinical needs and is committed to hepatitis B, cancer, the development of innovative medicines and improved new medicines in areas such as severe infections and gynecology. According to the latest national drug registration classification principle, In our R&D pipeline, There are Classes 1 of First in Class/Best in Class; and also exclusive patented products for fixed-dose combinations.
The Gritpharma is a leading company in the field of consistency evaluation technology services and has successfully completed dozens of pharmaceutical research tasks. We have extensive experience in dosage forms such as tablets, capsules, granules, dispersible tablets, suspensions, and many high-variation varieties. Many products have passed pre-BE or BE research! The company has developed strict internal control standards and research QA to manage data integrity, traceability, scientific and normative, to ensure data reliability.
Consistence Evaluation Services
Unique Generic Drug Development
The Gritpharma has a unique strategy on generic drug development, It is our characteristic to develop characteristic generic drugs according to the consistency evaluation idea and provide high-quality process technology and services for downstream pharmaceutical companies. At the same time, using high-level research and development strength and national policies to encourage research and innovation of the spring, according to MAH policy dividends……
The Gritpharma not only has a rich product line in the development of small molecule drugs, but also actively deploys biopharmaceuticals in recent years. On the one hand, we cooperates with domestic scientific research institutions, on the other hand, we introduces foreign advanced technologies and products actively. At present, we have signed a comprehensive strategic cooperation agreement with Juventas Therapeutics of the United States of up to 200 million RMB.